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Skin lesions are frequently encountered in clinical practice which can be a presentation of
systemic diseases not excluding an occult malignancy. Commonly reported paraneoplastic
dermatologic manifestations include acanthosis nigricans, dermatomyositis, erythroderma,
hypertrophic osteoarthropathy, Sweet syndrome, and paraneoplastic pemphigus (PNP).
PNP is a rare autoimmune mucocutaneous disease characterized by severe stomatitis, polymor-
phic skin eruptions, and associated underlying neoplasms most commonly non-Hodgkin’s lym-
phoma, chronic lymphocytic leukemia, and Castleman disease. PNP is characterized on
histopathology as dyskeratotic epithelial cells with acantholysis with a typical immunofluores-
cence staining pattern of direct and/or indirect staining of intercellular, basement membrane,
and dermoepidermal junction with immunoglobulin-G and C3. PNP has been described to have
poor prognosis with a mortality range of 75–90% and a mean survival of less than 1 year.
We describe a previously unreported case of PNP associated with acute myeloid leukemia (AML)
where the patient presented with a nonhealing ulcer and hemorrhagic crusting on the face that
did not respond to antimicrobials and steroids. Investigations revealed leukocytosis with periph-
erally circulating blasts. Skin biopsy revealed an evolving PNP and bonemarrow biopsy confirmed
evidence of AML. The patient underwent induction, consolidation, and then successful allogenic
bone marrow transplantation with complete remission. The skin lesion, which was initially
refractory to treatments, surprisingly resolved within 7 days of starting induction chemotherapy.sburgh, PA
nosis and
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remission ..., Hematol Oncol Stem CelIn this case, the skin lesion was a key factor in early diagnosis and instituting treatment for the
underlying AML. Early intervention gave our patient a better outcome with an ongoing survival of
18 months since diagnosis, maintaining complete remission.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
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nd/4.0/).Fig. 1 Gross appearance of the skin lesion.Introduction
Skin lesions are most commonly seen secondary to an infec-
tious, autoimmune or allergic etiology. In some instances,
skin lesions can be a manifestation of the myriad of systemic
diseases including malignancies. The dermatologic involve-
ment of the neoplasia can either be a primary tumor of
the integumentary system, metastasis to the skin as in
chloroma, or a paraneoplastic phenomenon. Commonly
reported paraneoplastic skin manifestations include acan-
thosis nigricans, dermatomyositis, erythroderma, hyper-
trophic osteoarthropathy, Sweet syndrome, and
paraneoplastic pemphigus (PNP) [1].
PNP presents as polymorphic cutaneous eruptions in the
form of either bullous, erythematous, or verrucous papules
or plaques, with or without intraoral mucosal involvement
in the form of stomatitis, erosions, or ulcerations. It can
also involve other mucosal regions, often the conjunctiva.
The incidence of PNP does not follow any geographic dis-
tribution or gender preponderance with a mean age at diag-
nosis of 51 years [2]. It has been associated with non-
Hodgkin lymphoma, chronic lymphocytic leukemia, Castle-
man disease, thymoma, and rarely with Waldenstrom
macroglobulinemia, Hodgkins lymphoma, and monoclonal
gammopathy [3,4]. It has also been reported with solid
tumor malignancies like adenocarcinoma of the pancreas,
colon, breast, and prostate, as well as mesenchymal sarco-
mas [5]. Occasionally, medications like fludrabine and
interferon-a have been shown to cause a flare up of PNP
lesions in known patients [6].
We report a case of PNP associated with acute myeloid
leukemia (AML) previously unreported in medical literature.
This atypical presentation of AML as PNP led to the early
diagnosis, treatment, and complete remission of the
patient.
Case report
A 59-year-old man, with no significant past medical history,
presented to his primary care physician with a lesion on his
face. He had a recent molar tooth extraction 1 month pre-
vious with no associated complications. He was a current
smoker with a 20-pack-year smoking history. He had a fam-
ily history of lung cancer, colon cancer, and uterine cancer,
and no personal or family history of any autoimmune
disease.
The lesion was just limited to his lower face around the
perioral area. The patient denied any recent infection,
rashes, swollen lymph nodes, fever, night sweats, bleeding,
or any pain. He had no recent history of travel, trauma,
insect, tick or animal bite, or any exposure to sick contacts.
He did complain of stomatitis but without any oral ulcers.iqui S et al., Paraneoplastic pemphi
l Ther (2016), http://dx.doi.org/10On physical examination, the lesions were black, indu-
rated, and ulcerated, with hemorrhagic crusting involving
the entire lower lip along the vermilion border and infrana-
sal area (Fig. 1). No other skin lesions were identified. There
was no palpable cervical or peripheral lymphadenopathy,
petechial rash, buccal lesions, or oral ulceration.
Considering the lesion to be a bacterial infection, he was
initially treated with oral antimicrobials as an outpatient.
With no clinical improvement, routine investigations were
done that revealed leukocytosis with peripherally
circulating blasts (Fig. 2) raising concern for a hematologi-
cal malignancy, for which he was referred to our inpatient
hematology service.
Complete blood count revealed a white cell count of
24,300/uL with 29% blasts and no bandemia, platelet count
of 33,000/uL, hemoglobin of 9.1 g/dL, and hematocrit of
27. Other investigations revealed elevated lactate dehydro-
genase of 664 mg/dL (normal: 140–280 mg/dL) and normal
uric acid of 6.4 mg/dL (normal: 3.4–7.0 mg/dL). There
was no evidence of disseminated intravascular coagulation
and other laboratory tests including serum sodium, potas-
sium, blood urea nitrogen, creatinine, and liver function
tests were normal. Serum protein electrophoresis also did
not reveal any monoclonal bands.
The patient was initially started on empiric antimicrobial
coverage with valacyclovir, vancomycin, cefepime, and
micafungin, along with dexamethasone, due to concerns
of being in an immunocompromised state. A bone marrow
biopsy along with a biopsy of the skin lesion was then
pursued.
Microbiological analysis of the skin biopsy showed no
evidence of herpes simplex virus in tissue culture, absence
of viral cytopathic changes, or any fungal elements.
Epstein-Barr virus DNA polymerase chain reaction was also
negative. Wound cultures grew mixed oropharyngeal bacte-
rial flora with few Candida albicans. Skin lesions remainedgus as a presentation of acute myeloid leukemia: Early diagnosis and
.1016/j.hemonc.2016.05.003
Fig. 2 Peripheral blood smear at 60 magnification showing
abundance of immature myeloid cells.
Fig. 3 Skin biopsy at 400 magnification showing mixed
inflammatory infiltrates deep to the ulcer. Largely neutrophilic
with occasional larger leukemic cells (high nuclear to cytoplas-
mic ratio, scant cytoplasm, and immature chromatin with
prominent nucleoli). Inset: cells positive for CD117, similar to
ones seen in bone marrow (Fig. 5).
Fig. 4 Skin biopsy at 20 magnification showing ulceration
and focal adjacent acantholysis.
Fig. 5 Bone marrow biopsy at 20 magnification: increased
number of large, immature myeloid cells (nuclei are eccentric,
hyposegmented, high nucleus-to-cytoplasm ratio, scant cyto-
plasm, fine chromatin, distinct nucleoli). Inset shows immature
cells positive for CD117.
Paraneoplastic pemphigus diagnosis and remission 3unchanged despite the patient being on broad-spectrum
antimicrobial therapy as well as corticosteroids. The skin
biopsy showed focal basal vacuolar change with dyskera-
totic keratinocytes, adjacent focal acantholysis (Figs. 3
and 4), and direct immunofluorescence (DIF) showed
positive immunoreactivity for complement C3 in a linear
pattern along the dermoepidermal junction but negative
for immunoglobulin (Ig)G, IgA, IgM; consistent with an
evolving PNP.
Bone marrow studies revealed hypercellularity of 60%,
dysmyelopoesis, erythroid–megaloblastoid change with
immunohistochemistry and flow cytometry showing pre-
dominant myeloperoxidase-positive myeloid immature cells
with 47% myeloblasts, 50% CD117-positive immature cells,
and 20% CD34-positive blasts, suggestive of AML. Human
leukocyte antigen-antigen D related and CD11c was present
excluding acute promyelocytic leukemia (Figs. 5 and 6).Please cite this article in press as: Siddiqui S et al., Paraneoplastic pemphi
remission ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.The patient was started on induction therapy with
cytarabine and idarubicin with rapid first complete remis-
sion. Surprisingly, the skin lesions, which were refractory
to the above-mentioned treatments, resolved within 7 days
of starting induction chemotherapy.
Further AML risk stratification studies showed intermedi-
ate risk normal cytogenetics and high risk ‘‘fms-like tyro-
sine kinase 3 gene internal tandem duplication” positivity.
After three cycles of high dose cytarabine consolidation,
he underwent successful matched unrelated donor allogenic
stem cell transplantation with complete remission and sub-
sequent recovery of his hematological cell counts. Post-
transplant chimerism studies revealed 100% donor status
in all his three cellular compartments. His post-transplant
course did get complicated with limited graft versus host
disease (GVHD) of the skin, which was successfully treated
with topical steroids, and BK-virus hemorrhagic cystitis,
which has also resolved.gus as a presentation of acute myeloid leukemia: Early diagnosis and
1016/j.hemonc.2016.05.003
Fig. 6 Bone marrow biopsy at 4 magnification showing
hypercellularity.
4 S. Siddiqui et al.Eighteen months after diagnosis and seven months post-
transplantation the patient is doing well with stable hema-
tological cell counts.
Discussion
PNP was first described in 1990 by Anhalt et al. [7] in a case
series of five patients with ulcerative, blistering mucocuta-
noeus disease, and pemphigus-like autoantibodies. The
polymorphic cutaneous lesions of PNP have been described
as bullae, erythematous, and verrucous papules or plaques,
which vary from features of pemphigus, pemphigoid, ery-
thema multiforme, GVHD, and lichen planus. Often it has
multiple overlapping features from this spectrum [6,8].
Intraoral mucosal involvement from intractable stomatitis
to multiple diffuse erosions and shallow ulcerations are also
seen, with occasional bloody crusts on the vermilion border
of lip as seen in this case (Fig. 1) [3,6]. Mucosal involvement
is varied which could include the oral, laryngeal, pharyn-
geal, esophageal, lingual, gingival, labial, gastrointestinal,
vaginal, or penile mucosa [3,9]. Conjunctiva is also very fre-
quently involved in the form of pseudomembranous con-
junctivitis which later evolves to scarring [3,10].
Camisa and Helm [9] proposed the PNP diagnostic crite-
ria which are modified criteria from Anhalt et al. [7].
According to the diagnostic criteria PNP can be diagnosed
by the presence of either all three major or two major with
two minor criteria as described in Table 1 [9].
In their article, Camisa and Helm [9] described the com-
mon histologic findings such as acantholysis, keratinocyte
necrosis, lichen-like inflammatory infiltrates, and der-
moepidermal blisters. They also described DIF showing C3
and/or IgG deposits on epithelial cell surfaces and
dermoepidermal junctions or both, and indirect immunoflu-
orescence (IIF), which is commonly done on monkey esoph-
agus or rat bladder epithelium, with intercellular staining
and/or dermoepidermal staining [9]. This case had two
major criteria of polymorphic skin eruption and concurrent
neoplasia along with two minor criteria of histological signs
of acantholysis and DIF showing staining of C3 immunoreac-Please cite this article in press as: Siddiqui S et al., Paraneoplastic pemphi
remission ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10tivity at dermoepidermal junctions. PNP antibodies that
have been implicated are most commonly anti-envoplakin
and anti-periplakin antibodies. Other antibodies include
bullous pemphigoid antigen 1, desmoplakin I and II,
desmoglein-1 and desmoglein-3 [6,11,12]. Recent research
has reported the association of PNP with alpha-2-macro-
globulin-like protein 1 and anti-desmocollin antibodies as
well [13].
Joly et al. [14] reviewed the various criteria for PNP in
their study. They reported that high sensitivity and
specificity was associated with factors such as lymphoprolif-
erative disorders, IIF positivity on rat bladder, and
immunoblotting of antibodies against envoplakin and peri-
plakin. While low sensitivity and high specificity was associ-
ated with factors like polymorphic eruption, typical
histology, DIF, or immunoblotting of antibodies against
desmoplakin and bullous pemphigoid antigen 1 [3,14].
Besides the cancers, PNP is also associated with diseases
like myasthenia gravis (MG) and bronchiolitis obiliterans
(BO) [3,11,12]. BO is an irreversible and fatal disease that
occurs in lung transplant recipients and in chronic GVHD
patients after allogenic hematopoietic stem cell transplan-
tation, with an incidence of 30–40% PNP patients progress-
ing to BO [15,16]. Respiratory compromise in BO occurs due
to the intraluminal shedding of respiratory mucosal epithe-
lium after an immunological attack due to the preponder-
ance of desmoplakins [3]. Such patients present with
worsening exertional dyspnea that culminates to severe dys-
pnea, disproportionate to the chest x-ray and arterial blood
gas findings [10]. Most of the PNP-associated BO is fatal,
except for those with Castleman disease [15,16]. In a study
of 104 patients, BO developed in 20 patients with 16 of them
resulting in death [13]. This study also reported the deaths
of 40 PNP patients with infectious causes, mainly pneumo-
nia, which can be attributed to the impaired immunity with
their lymphoproliferative disorder. With regards to the asso-
ciation with MG, a study on 58 PNP patients where 39% of
them complained of muscle weakness, 35% were diagnosed
with MG with positive antiacetylcholine receptor and anti-
acetylcholinesterase antibodies [12]. The antiacetylcholine
receptor and antiacetylcholinesterase antibodies levels
were significantly elevated in patients who had dyspnea.
Even though PNP and MG have both been associated with
thymoma, this study found no significant differences in pos-
itivity and levels of these autoantibodies between PNP with
Castleman disease and thymoma [12]. This reflects that MG
can be independent sequelae of PNP irrespective of the
underlying thymoma. Thus, patients with PNP who develop
muscle weakness or dyspnea warrant additional workup
for ruling out BO and MG and patients need to be educated
on these complications.
The most effective treatment for PNP is the resection or
resolution of the underlying neoplasm which has shown suc-
cess in patients with Castleman disease as well as reported
in this case of AML [17]. High-dose systemic corticosteroids
and immunosuppression with azathioprine and mycopheno-
late for treatment have been also recommended [6].
Rituximab is also proposed for the treatment which acts
by reducing B cells that produce the PNP antibodies that
may have caused the skin lesions to develop [15,18]. Intra-
venous Igs have also been tried as a treatment [17].
Although our patient was given dexamethasone, which wasgus as a presentation of acute myeloid leukemia: Early diagnosis and
.1016/j.hemonc.2016.05.003
Table 1 Paraneoplastic pemphigus (PNP) diagnostic criteria as described by Camisa and Helm [9].
PNP diagnostic criteria (presence of either all three major or two major with two minor criteria)
Major
Polymorphic mucocutaneous eruption
Concurrent internal neoplasia
Serum antibodies
Minor
Histological signs of acantholysis in biopsy specimen from at least one anatomic site of involvement
DIF staining of perilesional tissue showing intercellular and basement membrane zone immunoreactants
IIF positive cytoplasmic staining of rat bladder epithelium
DIF = direct immunofluorescence; IIF = indirect immunofluorescence.
Paraneoplastic pemphigus diagnosis and remission 5ineffective, the skin lesions dramatically responded to the
successful induction regimen which supports the fact that
treatment of the underlying neoplasm leads to its resolution
in patients with AML. Different types of PNP respond vari-
ably to treatment regimens as rituximab has been proposed
to be very effective in patients with follicular lymphoma.
PNP can be categorized as being severe if having exten-
sive skin involvement (with a minimum of 20 skin lesions)
with or without mucosal lesions or if there is involvement
of at least two mucosal areas or oral mucosa only causing
dysphagia or weight loss [9].
Patients with PNP have a poor prognosis with a reported
mortality rate of 75–90% and a mean survival of less than
1 year [6]. According to one multicenter study on 53
patients; the 1-year, 3-year, and 5-year survival rates were
49%, 41%, and 38%, respectively, with the main causes of
death being infections, progression of cancer, and respira-
tory failure due to suspected BO [6]. This study also listed
the poor prognostic factors such as the presence of ery-
thema multiforme-like skin lesions and histological evidence
of keratinocyte necrosis especially when associated with
severe skin or mucosal involvement [6]. Castleman disease
was associated with better survival while non-Hodgkin lym-
phoma had a shorter survival with age, gender, or presence
of PNP antibodies having no association with prognosis. Our
case had a better outcome likely due to early diagnosis and
treatment, with complete remission of AML. It can be pro-
posed that AML-associated PNP may have a better survival
rate than other ones, similar to Castleman disease. Similar
to previously reported PNP in Castleman disease, where
treatment of primary malignancy resulted in resolution of
the skin disease, this case also demonstrated the effective
resolution of skin lesions with treatment of primary malig-
nancy [19].
Our case met the diagnosis criteria by Camisa and Helm
[9] but further testing for autoantibodies and IIF would have
been more confirmatory. The typical histopathology and IIF
pattern of PNP may take several months to completely
develop, so even in suspected cases where the skin biopsy
does not fully meet the criteria stated above, it may still
signify that the PNP is in the process of evolving [6]. In such
cases it is prudent to consider it as an evolving PNP and pro-
ceed with screening for related neoplasms.
Skin lesions are commonly seen in practice, which
besides being a common garden variety skin infection or
autoimmune disease, can also be a manifestation of an
underlying systemic disease. Some lesions may be resilientPlease cite this article in press as: Siddiqui S et al., Paraneoplastic pemphi
remission ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/10.to conventional treatment like antimicrobials or immuno-
suppressants, as seen in our case, which should be followed
with a skin biopsy. Clinicians should remember that skin
lesions, as a paraneoplastic phenomenon, could be a sign
of an occult malignancy where early diagnosis and interven-
tion are crucial. Thus, any unexplained or treatment refrac-
tory skin lesions should invoke a suspicion of paraneoplastic
phenomenon followed by immediate screening for age, sex,
and risk-factor appropriate neoplasms.
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